From: europeanpharmaceuticalreview.com The radionuclide treatment combines radioactive iodine therapy with single-domain antibodies to target the HER2 antigen. A Phase I trial has found that radionuclide treatment may offer new therapeutic options for human epidermal growth factor receptor type 2 (HER2)-positive breast cancer. The treatment combines radioactive iodine therapy with single-domain antibodies that target the HER2 antigen to destroy cancer cells. …
-
-
Missing a Deadline After a Breast Cancer Diagnosis
-
Does Discipline Make A Difference in Getting Breast Cancer?
-
Regrets After a Cancer Diagnosis
-
You Are Not Alone After a Breast Cancer Diagnosis
-
The Past and Future Collide After a Breast Cancer Diagnosis
